Compare Schrödinger, Inc. with Similar Stocks
Stock DNA
Software Products
USD 938 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.20
-48.26%
2.92
Revenue and Profits:
Net Sales:
59 Million
(Quarterly Results - Mar 2026)
Net Profit:
-60 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
26.04%
0%
26.04%
6 Months
-13.44%
0%
-13.44%
1 Year
-29.1%
0%
-29.1%
2 Years
-29.01%
0%
-29.01%
3 Years
-57.78%
0%
-57.78%
4 Years
-42.64%
0%
-42.64%
5 Years
-78.34%
0%
-78.34%
Schrödinger, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.81%
EBIT Growth (5y)
-194.15%
EBIT to Interest (avg)
-149.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.33
Sales to Capital Employed (avg)
0.47
Tax Ratio
0.51%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.92
EV to EBIT
-3.25
EV to EBITDA
-3.37
EV to Capital Employed
-8.80
EV to Sales
2.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-48.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 57 Schemes (37.81%)
Foreign Institutions
Held by 120 Foreign Institutions (27.25%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
58.60
59.60
-1.68%
Operating Profit (PBDIT) excl Other Income
-47.30
-49.30
4.06%
Interest
0.00
0.00
Exceptional Items
-13.50
-13.10
-3.05%
Consolidate Net Profit
-60.00
-59.80
-0.33%
Operating Profit Margin (Excl OI)
-832.80%
-854.50%
2.17%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -1.68% vs 62.84% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -0.33% vs -9.32% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
255.90
207.50
23.33%
Operating Profit (PBDIT) excl Other Income
-160.90
-203.10
20.78%
Interest
0.00
0.00
Exceptional Items
48.20
5.70
745.61%
Consolidate Net Profit
-103.30
-187.10
44.79%
Operating Profit Margin (Excl OI)
-652.30%
-1,008.50%
35.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 23.33% vs -4.25% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 44.79% vs -559.71% in Dec 2024
About Schrödinger, Inc. 
Schrödinger, Inc.
Software Products
Schrodinger, Inc. provides computational software solutions for drug discovery to the biopharmaceutical industry. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. Its platform integrates solutions for predictive modeling, data analytics and collaboration. Its wholly-owned programs include SDGR1, SDGR2, SDGR3, SDGR4 and SDGR5. SDGR1 and SDGR2 drug discovery programs are focused on targets that mediate deoxyribonucleic acid (DNA) repair, cell cycle regulation, replication stress responses, and apoptosis, or programmed cell death. SDGR3, SDGR4 and SDGR5 drug discovery programs are focused on genetically-defined cancers.
Company Coordinates 
Company Details
120 WEST 45TH STREET, 17TH FLOOR , NEW YORK NY : 10036
Registrar Details






